Diadema Partners LP Trevi Therapeutics, Inc. Transaction History
Diadema Partners LP
- $328 Billion
- Q2 2025
A detailed history of Diadema Partners LP transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 185,830 shares of TRVI stock, worth $2.25 Million. This represents 0.31% of its overall portfolio holdings.
Number of Shares
185,830
Previous 180,000
3.24%
Holding current value
$2.25 Million
Previous $1.13 Billion
10.22%
% of portfolio
0.31%
Previous 0.3%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
177Shares Held
111MCall Options Held
1.07MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$160 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$124 Million2.96% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$103 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$70.6 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.49MShares$54.3 Million5.2% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $706M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...